Phase 3 clinical trials of biosimilars are beneficial for patients because they do not have to be afraid of receiving a placebo. They receive either the reference product or the biosimilar, so that they receive treatment in any case.
In addition, it may be interesting for biosimilar developers to have studies conducted in countries where the price-performance ratio is better. Depending on the country, this can also be a great advantage for patients, as the study in their country creates access to the drug in the first place, since it was not even available before.
Covid-19 may also change the way studies are conducted. Virtual clinical testing, on-site administration and remote visits as part of the future clinical test standard can prevent long-distance trips to the site where the study is conducted. It could also be made possible to train doctors in hospitals that are closer to the patient and thus allow the study to take place at several locations.